UT Arlington Lands First-in-U.S. Biotech Discovery Platform to Accelerate Antibody Innovation
The University of Texas at Arlington has acquired a first-in-the-U.S. biotech discovery platform designed to significantly accelerate antibody research and therapeutic development. The system enables rapid single-cell analysis and identification of highly targeted antibodies, supporting advancements in cancer immunotherapy, infectious disease, and precision medicine. This milestone strengthens UTA’s role as a growing biotech hub in North Texas while expanding industry collaboration, workforce training, and translational research capabilities. 
UT Arlington Lands First-in-U.S. Biotech Discovery Platform to Accelerate Antibody Innovation